Skip to main content

Advertisement

SpringerLink
Log in

PQ-69, a novel and selective adenosine A1 receptor antagonist with inverse agonist activity

  • Original Article
  • Published:
Purinergic Signalling Aims and scope Submit manuscript

Abstract

Potent and selective adenosine A1 receptor (A1AR) antagonists with favourable pharmacokinetic properties used as novel diuretics and antihypertensives are desirable. Thus, we designed and synthesized a series of novel 4-alkylamino substitution-2-arylpyrazolo[4,3-c]quinolin-3-one derivatives. The aim of the present study is to characterize the biological profiles of the optimized compound, PQ-69. In vitro binding assay revealed a K i value of 0.96 nM for PQ-69 in cloned hA1 receptor, which was 217-fold more selective compared with hA2A receptors and >1,000-fold selectivity for hA1 over hA3 receptor. The results obtained from [35S]-GTPγS binding and cAMP concentration assays indicated that PQ-69 might be an A1AR antagonist with inverse agonist activity. In addition, PQ-69 displayed highly inhibitory activities on isolated guinea pig contraction (pA2 value of 8.99) induced by an A1AR agonist, 2-chloro-N6-cyclopentyl adenosine. Systemic administration of PQ-69 (0.03, 0.3, 3 mg/kg) increased urine flow and sodium excretion in normal rats. Furthermore, PQ-69 displayed better metabolic stability in vitro and longer terminal elimination half-life (t 1/2) in vivo compared with 1,3-dipropyl-8-cyclopentylxanthine. These findings suggest that PQ-69 exhibits potent antagonist effects on A1AR in vitro, ex vivo and in vivo, it might be a useful research tool for investigating A1AR function, and it could be developed as a potential therapeutic agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Scheme 1
Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fredholm BB, IJzerman AP (2011) International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 63:1–34

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Sebastião AM, Ribeiro JA (2009) Adenosine receptors and the central nervous system. Handb Exp Pharmacol 193:471–534

    Article  PubMed  Google Scholar 

  3. Chen JF, Eltzschig HK, Fredholm BB (2013) Adenosine receptors as drug targets—what are the challenges? Nat Rev Drug Discov 12:265–286

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Modlinger PS, Welch WJ (2003) Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 12:497–502

    Article  CAS  PubMed  Google Scholar 

  5. Schenone S, Brullo C, Musumeci F, Bruno O, Botta M (2010) A1 receptors ligands: past, present and future trends. Curr Top Med Chem 10:878–901

    Article  CAS  PubMed  Google Scholar 

  6. Müller CE, Jacobson KA (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 1808:1290–1308

    Article  PubMed Central  PubMed  Google Scholar 

  7. de Ligt RA, Kourounakis AP, IJzerman AP (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130:1–12

    Article  PubMed Central  PubMed  Google Scholar 

  8. Searl TJ, Silinsky EM (2012) Evidence for constitutively-active adenosine receptors at mammalian motor nerve endings. Eur J Pharmacol 685:38–41

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. He W, Wilder T, Cronstein BN (2013) Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist. Br J Pharmacol 170:1167–1176

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Liu CH, Wang B, Li WZ, Yun LH, Liu Y, Su RB, Li J, Liu H (2004) Design, synthesis, and biological evaluation of novel 4-alkylamino-1-hydroxyl-methylimidazo [1,2-a] quinoxalines as adenosine A1 receptor antagonists. Bioorg Med Chem 12:4701–4707

    Article  CAS  PubMed  Google Scholar 

  11. von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glaumann H (1980) Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther 27:711–725

    Article  Google Scholar 

  12. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ (1998) Comparative pharmacology of human adenosine receptor subtypes—characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 357:1–9

    Article  CAS  PubMed  Google Scholar 

  13. Cheng YC, Prusoff WH (1973) Mouse ascites sarcoma 180 thymidylate kinase. General properties, kinetic analysis, and inhibition studies. Biochemistry 12:2612–2619

  14. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48–58

  15. Mandagere AK, Thompson TN, Hwang KK (2002) Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304–311

    Article  CAS  PubMed  Google Scholar 

  16. Zhuang XM, Deng JT, Li H, Kong WL, Ruan JX, Xie L (2011) Metabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes. Acta Pharmacol Sin 32:1276–1284

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Karasawa A, Kubo K, Shuto K, Oka T, Nakamizo N (1988) Antihypertensive effects of the new calcium antagonist benidipine hydrochloride in rats. Arzneimittelforschung 38:1684–1690

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

These studies were supported by the National Science and Technology Major Projects “Major New Drugs Innovation and Development” (2009ZX09103-021) and Beijing Municipal Science & Technology Commission “Z121102002512046”.

Author information

Authors and Affiliations

  1. Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Beijing, 100850, China

    Min Lu, Bo Wang, Cheng Zhang, Xiaomei Zhuang, Mei Yuan, Haoshan Wang, Weizhang Li, Ruibin Su & Jin Li

Authors
  1. Min Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bo Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaomei Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mei Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haoshan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weizhang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ruibin Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin Li.

Additional information

Authors’ Contributions

Min Lu and Bo Wang designed the study and wrote the article. W.Z.L., H.S.W. and C.Z. synthesized PQ-69. X.M.Z. and M.Y. performed acquisition analysis and interpretation of pharmacokinetic data. R.B.S. and J.L. initiated the research project.

Min Lu and Bo Wang contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 93.4 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, M., Wang, B., Zhang, C. et al. PQ-69, a novel and selective adenosine A1 receptor antagonist with inverse agonist activity. Purinergic Signalling 10, 619–629 (2014). https://doi.org/10.1007/s11302-014-9424-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11302-014-9424-5

Keywords

Search

Navigation